DK1274721T3 - Hamostatisk aktivt vWF-holdigt præparat samt fremgangsmade til fremstilling heraf - Google Patents

Hamostatisk aktivt vWF-holdigt præparat samt fremgangsmade til fremstilling heraf

Info

Publication number
DK1274721T3
DK1274721T3 DK01938084T DK01938084T DK1274721T3 DK 1274721 T3 DK1274721 T3 DK 1274721T3 DK 01938084 T DK01938084 T DK 01938084T DK 01938084 T DK01938084 T DK 01938084T DK 1274721 T3 DK1274721 T3 DK 1274721T3
Authority
DK
Denmark
Prior art keywords
vwf
preparation
fraction
active
composition
Prior art date
Application number
DK01938084T
Other languages
Danish (da)
English (en)
Inventor
Djuro Josic
Monika Stadler
Gerhard Gruber
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Application granted granted Critical
Publication of DK1274721T3 publication Critical patent/DK1274721T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01938084T 2000-04-18 2001-04-04 Hamostatisk aktivt vWF-holdigt præparat samt fremgangsmade til fremstilling heraf DK1274721T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108430A EP1148063A1 (de) 2000-04-18 2000-04-18 Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
DK1274721T3 true DK1274721T3 (da) 2006-02-13

Family

ID=8168496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01938084T DK1274721T3 (da) 2000-04-18 2001-04-04 Hamostatisk aktivt vWF-holdigt præparat samt fremgangsmade til fremstilling heraf

Country Status (24)

Country Link
US (2) US7166709B2 (zh)
EP (2) EP1148063A1 (zh)
JP (1) JP4976634B2 (zh)
KR (1) KR100685448B1 (zh)
CN (1) CN100448888C (zh)
AT (1) ATE306494T1 (zh)
AU (2) AU6383501A (zh)
BR (1) BR0110193A (zh)
CA (1) CA2406626C (zh)
CZ (1) CZ303932B6 (zh)
DE (1) DE50107689D1 (zh)
DK (1) DK1274721T3 (zh)
EA (1) EA006209B1 (zh)
EE (1) EE200200595A (zh)
ES (1) ES2247117T3 (zh)
HU (1) HU225992B1 (zh)
IL (2) IL152173A0 (zh)
MX (1) MXPA02010017A (zh)
NO (1) NO324773B1 (zh)
RS (1) RS50835B (zh)
SI (1) SI1274721T1 (zh)
UA (1) UA76714C2 (zh)
WO (1) WO2001079260A1 (zh)
ZA (1) ZA200208396B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
CA2710762A1 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN102076855A (zh) 2008-06-24 2011-05-25 Csl百灵有限公司 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物
DK2349314T3 (da) 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
BR112012030455B1 (pt) * 2010-06-01 2021-08-17 Baxter Healthcare S.A. Processo para fabricar uma composição hemostática seca e estável, recipiente acabado final, e, kit para administrar uma composição hemostática
KR20130112031A (ko) * 2010-09-20 2013-10-11 옥타파마 아게 피브리노겐의 생산 방법
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
US10064406B2 (en) * 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products
MX351340B (es) 2012-03-13 2017-10-11 Octapharma Ag Proceso mejorado para la produccion de fibrinogeno y fibrinogeno producido por este.
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
ATE85221T1 (de) 1988-11-05 1993-02-15 Octapharma Ag Verfahren zur herstellung eines hochreinen, nicht infektioesen antihaemophiliefaktors mittels chromatographie.
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
EP0674531A1 (de) * 1992-12-16 1995-10-04 IMMUNO Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT404358B (de) * 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
HUP0301211A2 (hu) 2003-07-28
DE50107689D1 (de) 2006-02-23
AU6383501A (en) 2001-10-30
JP2004516231A (ja) 2004-06-03
KR20030019352A (ko) 2003-03-06
EP1274721B1 (de) 2005-10-12
WO2001079260A1 (de) 2001-10-25
CZ20023454A3 (cs) 2003-05-14
CA2406626A1 (en) 2001-10-25
YU78402A (sh) 2006-08-17
EP1274721A1 (de) 2003-01-15
ES2247117T3 (es) 2006-03-01
JP4976634B2 (ja) 2012-07-18
EA006209B1 (ru) 2005-10-27
US20030138913A1 (en) 2003-07-24
NO324773B1 (no) 2007-12-10
ATE306494T1 (de) 2005-10-15
SI1274721T1 (sl) 2006-04-30
BR0110193A (pt) 2003-02-11
CN1425024A (zh) 2003-06-18
UA76714C2 (uk) 2006-09-15
HUP0301211A3 (en) 2005-12-28
NO20025007D0 (no) 2002-10-17
IL152173A (en) 2007-07-24
US20070232791A1 (en) 2007-10-04
MXPA02010017A (es) 2003-04-25
NO20025007L (no) 2002-11-28
AU2001263835B2 (en) 2005-06-09
HU225992B1 (en) 2008-02-28
EP1148063A1 (de) 2001-10-24
ZA200208396B (en) 2004-04-30
US7985846B2 (en) 2011-07-26
CA2406626C (en) 2012-02-21
EA200201104A1 (ru) 2003-04-24
PL358388A1 (en) 2004-08-09
CZ303932B6 (cs) 2013-07-03
IL152173A0 (en) 2003-05-29
US7166709B2 (en) 2007-01-23
RS50835B (sr) 2010-08-31
EE200200595A (et) 2004-04-15
KR100685448B1 (ko) 2007-02-23
CN100448888C (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
DK1274721T3 (da) Hamostatisk aktivt vWF-holdigt præparat samt fremgangsmade til fremstilling heraf
DE69328519T2 (de) Chondroitinase, Herstellungsverfahren und pharmazeutische Zusammensetzung
DE69131580T2 (de) GDF-1 und UOG1 Proteine
DE3684078D1 (de) Reinigung und aktivierung von proteinen aus unloeslichen einschlusskoerpern.
DE3684350D1 (de) Reinigung des immunoglobulins g.
SE9803838D0 (sv) A chromatography method and a column material useful in said method
DK0911037T3 (da) Ved stuetemperatur lagringsholdbart immunoglobulinpræparat til intravenøs injektion
ES2150233T3 (es) Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.
ATE277073T1 (de) Verfahren und vorrichtung zur herstellung von gereinigten plasmaproteinen
BR9814224A (pt) Composto, e, processo para produzir o mesmo.
DE69803570T2 (de) Bipolare elektrolyseur mit ionenaustauscher membran
DK0567448T3 (da) Fremgangsmåde til fremstilling af faktor VIII
DE69535316D1 (de) Als lerk6 bezeichnetes cytokin
DE69636714D1 (de) G-CSF TPO Fusionsproteine
IT8620548A0 (it) Procedimento e dispositivo per la fabbricazione di prodotti in fibra di vetro, per esempio veli, feltri, filati e stoppini.
ES2149791T3 (es) Procedimiento para la inactivacion de virus en preparaciones de proteinas.
BR9302452A (pt) Composicao polimerica util como membrana,membrana e processo de formacao de membrana
DE29606714U1 (de) Parabolspiegel zur Konzentration von Sonnenlicht
ATE374812T1 (de) Methode zur herstellung von thrombin
KR960023054A (ko) 재조합 인간 에리스로포이에틴의 정제 방법
SE9302856D0 (sv) Method and means for producing a plasmapeotein-binding protein
KR940003567A (ko) 면역글로불린 a 및 m이 제거된 정맥주사용 감마글로불린제의 제조방법
KR930000679A (ko) 한국형 c형 간염 바이러스의 특이항원인 khcv ub-코아(ocre) 14단백질의 정제 방법
DK594786D0 (da) Glaslistesystem til fastholdelse af ruder i traevinduer
DE59707174D1 (de) Verfahren zur weiterleitung mit 100% leitungsauslastung von asynchron übertragenen nachrichtenzellen